- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04569045
Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds
February 23, 2022 updated by: SciVision Biotech Inc.
A Randomized, Within-subject Controlled Clinical Study to Evaluate the Safety and Effectiveness of Pain Relief of Modified Sodium Hyaluronate Gel for Injection When Used for the Correction of Moderate or Severe Nasolabial Folds
The aim of this study is to evaluate the safety and effectiveness of pain relief of modified sodium hyaluronate gel for injection when used for the correction of moderate or severe nasolabial folds.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
One hundred and thirty patients were enrolled and there two sides of nasolabial folds (NLF) were randomized to receive HA with lidocaine or HA.
The primary outcome was immediate visual analogue scale (VAS) of pain evaluated after injection for both NLF sides.
Secondary outcomes including VAS pain, wrinkle severity rating scale (WSRS), global aesthetic improvement scale (GAIS) and AE were observed at 1, 3, 6, 9, 12 follow-ups.
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- BEIJING
-
Shanghai, China
- Shanghai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 to 65 years of male or female
- Wrinkle Severity Rating Scale (WSRS) of bilateral nasolabial folds graded 3 or 4 by blinded evaluator (moderate to severe bilateral nasolabial fold), consistent grade of bilateral nasolabial folds, and the grades approved by the physician who perform the treatment
- Agree not to undergo any other under-eye facial surgery (including nose) during the study period
Exclusion Criteria:
- Injection site with infection or other skin diseases present which may affect the evaluation
- With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at nasolabial folds
- With permanent implants or planning to receive permanent implants during the study period at the injection sites
- Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 12 months
- With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period
- With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period
- With prescription medication for nasolabial fold treatment, topical corticosteroid, skinirritating topical products or pigmentation products within the past 2 weeks or planning to take these medication or products during the study period
- With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.)
- Severe liver or kidney defects (such as the value of ALT or AST over 1.5 folds of upper limit of normal value; the value of creatinine over 1.5 folds of upper limit of normal value)
- With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis removement medications
- With epilepsy or porphyria
- With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency
- With the need to take b-blocker during the study period
- With severe atrioventricular block (type 2 second-degree AV block and third-degree AV block)
- With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period
- With orthodontics, tooth extraction, tooth implantation (extraction or implantation of tooth anterior to the second premolar) or planning to receive these procedures during the study
- With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study
- Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change
- Pregnant, planning pregnancy or in breastfeeding females
- With syphilis or HIV infection
- Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HA + Lidocaine
Sodium Hyaluronate with Lidocaine Hydrochloride
|
20 mg
|
ACTIVE_COMPARATOR: HA
Sodium Hyaluronate
|
20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immediate VAS pain evaluated after injection for both NLF sides
Time Frame: Immediate post-injection
|
The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'.
|
Immediate post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events reported from the baseline and during the study period
Time Frame: 1, 3, 6, 9 and 12 months post-injection
|
The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period.
|
1, 3, 6, 9 and 12 months post-injection
|
VAS pain evaluated 15, 30, 45 and 60 minutes after injection for both NLF sides
Time Frame: 15, 30, 45 and 60 minutes post-injection
|
The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'.
|
15, 30, 45 and 60 minutes post-injection
|
On-site WSRS evaluated by site blinded-evaluator at 1, 3, 6, 9 and 12 months
Time Frame: 1, 3, 6, 9 and 12 months post-injection
|
Evaluators assess the wrinkle severity of nasolabial folds on site or photographically with 5 graded scale,1 to 5 was represented 'absent' to 'extreme'.
|
1, 3, 6, 9 and 12 months post-injection
|
GAIS evaluated photographically by independent blinded-evaluator at 1, 3, 6, 9 and 12 months
Time Frame: 1, 3, 6, 9 and 12 months post-injection
|
Evaluators and subjects assess the improvement of correction with 5 graded scale,1 to 5 was represented 'exceptional improvement' to 'worsened'.
|
1, 3, 6, 9 and 12 months post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 20, 2020
Primary Completion (ACTUAL)
December 4, 2020
Study Completion (ACTUAL)
December 10, 2021
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
September 23, 2020
First Posted (ACTUAL)
September 29, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 25, 2022
Last Update Submitted That Met QC Criteria
February 23, 2022
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- RDCT-CNFL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lidocaine
-
Derince Training and Research HospitalRecruiting
-
Kaohsiung Medical University Chung-Ho Memorial...Not yet recruiting
-
Inonu UniversityCompletedPain on Injection of Propofol,Lidocaine, Alkalinized LidocaineTurkey
-
University of PadovaRecruitingLidocaine | Anesthesia Brain MonitoringItaly
-
Khon Kaen UniversityNot yet recruitingIntubation | Hemodynamics | Laryngoscopy | Neurosurgery | LidocaineThailand
-
Galeno Desenvolvimento de Pesquisas ClínicasBiolab Sanus FarmaceuticaCompletedLidocaine Adverse Reaction | Prilocaine Adverse ReactionBrazil
-
King Edward Medical UniversityCompleted
-
Menoufia UniversityRecruitingDexmedetomidine | Laparoscopic Cholecystectomy | Propofol | Lidocaine | Hemodynamic ResponsesEgypt
-
Marina Ramsis Aziz GhalyRecruiting
-
Tanta UniversityCompletedOptic Nerve Sheath Diameter | Laparoscopic Hysterectomy | Lidocaine | TrendelenburgEgypt
Clinical Trials on HA+Lidocaine
-
National Cancer Centre, SingaporeSingapore General Hospital; Singhealth Duke-NUS Oncology Academic Clinical...Active, not recruiting
-
Galderma R&DTerminatedFacial Tissue AugmentationSweden
-
VA Office of Research and DevelopmentRecruitingPost-traumatic Stress DisorderUnited States
-
University Hospitals, LeicesterJafron Biomedical Company LimitedNot yet recruitingPilot Study on HA380 Column Use in Critically Ill Patients Receiving Extracorporeal Support. (HACEC)Inflammation | Acute Kidney Injury | ARDS | Extracorporeal Circulation; ComplicationsUnited Kingdom
-
Medy-ToxCompletedNasolabial FoldKorea, Republic of
-
TauTona GroupCompleted
-
Nitto Denko CorporationCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedSmall-Cell Lung CancerSwitzerland
-
Cancer Institute and Hospital, Chinese Academy...CompletedCognitive Function | Brain Metastases | Lung Neoplasm | Simultaneous Integrated Boost | Hippocampal AvoidanceChina